FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Moderate Growth Seen in Antidepressants

[ Price : $8.95]

Decision Resources projects modest sales growth for antidepressants in the next decade because of patent expirations in several le...

Neopharm Misses Phase 3 Endpoint with Cancer Drug

[ Price : $8.95]

Neopharm Inc. says a pivotal Phase 3 trial involving an experimental cancer drug failed to meet its efficacy endpoint.

Nature of Patient Conversations Affects Prescribing

[ Price : $8.95]

Researchers say doctors respond better to general requests for antidepressant medications rather than to requests for specific dru...

DTC Continues in New Zealand

[ Price : $8.95]

New Zealands government backs away from restricting drug DTC ads.

Gottlieb Resigns to Rejoin DC Think Tank

[ Price : $8.95]

FDA deputy commissioner for medical and scientific affairs Scott Gottlieb resigns his post at the agency to return to the conserva...

Injunction Against Apotex for Generic Plavix Upheld

[ Price : $8.95]

A federal appeals court judge keeps in place an injunction preventing Apotex from marketing its generic Plavix until a patent disp...

FDA Proposes Revised Rules on Experimental Drugs

[ Price : $8.95]

FDA says proposed rules on access to and charging for experimental drugs used in treatment should eliminate confusion that has exi...

FDA Class 1 Recall on Glucose Test Strips

[ Price : $8.95]

FDA classifies as Class 1 two earlier recalls involving counterfeit blood glucose test strips used in LifeScans One Touch monitor....

FDA Clears OTC Light Hair Removal System

[ Price : $8.95]

FDA clears a Palomar Medical Technologies 510(k) for an over-the-counter light-based hair removal device.

Gilead Will Comply with Subpoena, Probe

[ Price : $8.95]

The U.S. Attorney in San Francisco subpoenas marketing and medical education documents from Gilead Sciences for three HIV drugs.